The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01
- Other Titles
- The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01
- Authors
- 김영준; 김재용; 임재준; 성경수; 이지혜; Hyuk-Jin Oh; 강석구; Shin Hyuk Kang; Doo-Sik Kong; 김성환; Se-Hyuk Kim; 김세훈; 김유정; 김의현; 김인아; Ho Sung Kim; Tae Hoon Roh; Jae-Sung Park; Hyun Jin Park; Sang Woo Song; 양승호; Wan-Soo Yoon; 윤홍인; Soon-Tae Lee; Sea-Won Lee; 이연수; 위찬우; 장종희; Tae-Young Jung; 정혜림; 조재호; 최승홍; Hyoung Soo Choi; 홍제범; 임도훈; 정동섭
- Issue Date
- 2019
- Publisher
- 대한뇌종양학회
- Keywords
- Korean Society for Neuro Oncology; Guideline; Grade III Gliomas; Practice
- Citation
- Brain Tumor Research and Treatment, v.7, no.2, pp.63 - 73
- Journal Title
- Brain Tumor Research and Treatment
- Volume
- 7
- Number
- 2
- Start Page
- 63
- End Page
- 73
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4043
- DOI
- 10.14791/btrt.2019.7.e42
- ISSN
- 2288-2405
- Abstract
- Background: There was no practical guideline for the management of patients with central nervous system tumor in Korea in the past. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, developed the guideline for glioblastoma successfully and published it in Brain Tumor Research and Treatment, the official journal of KSNO, in April 2019. Recently, the KSNO guideline for World Health Organization (WHO) grade III cerebral glioma in adults has been established.
Methods: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searches in PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords. Scope of the disease was confined to cerebral anaplastic astrocytoma and oligodendroglioma in adults.
Results: Whenever radiological feature suggests high grade glioma, maximal safe resection if feasible is globally recommended. After molecular and histological examinations, patients with anaplastic astrocytoma, isocitrate dehydrogenase (IDH)-mutant should be primary treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy whereas those with anaplastic astrocytoma, NOS, and anaplastic astrocytoma, IDH-wildtype should be treated following the protocol for glioblastomas. In terms of anaplastic oligodendroglioma, IDH-mutant and 1p19q-codeletion, and anaplastic oligodendroglioma, NOS should be primary treated by standard brain radiotherapy and neoadjuvant or adjuvant PCV (procarbazine, lomustine, and vincristine) combination chemotherapy.
Conclusion: The KSNO's guideline recommends that WHO grade III cerebral glioma of adults should be treated by maximal safe resection if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Neurosurgery > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4043)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.